OS THERAPIES INC
OSTXNYSE AMERICAN🏆 #4214 by market capEarnings Nov 13US Equity
——
Quote unavailableTrack OSTX
Get earnings, price moves & breaking news on Telegram
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$58M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
No chart data available for OSTX.
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $1.15 – $2.25
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 46.8M
- Next Earnings
- 2026-11-13
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.07
- Dividend Yield
- —
- Dilution (1yr)
- −76.4%
OS THERAPIES INC
OSTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$29M▲ +321.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14.2B▲ +195423.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
29.3M▼ −76.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$270K▼ −$5M YoY
StockOtter · stockotter.spaceAbout OS THERAPIES INC
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.